At the annual ASCO meeting, new data on Merkel cell carcinoma, GLP-1s, and Grail's cancer detection tests were plentiful. Yet this year's proceedings were marked by an unusual undercurrent: oncologists openly grappling with grief.
Organizers dedicated sessions to the emotional toll of cancer care, acknowledging that data alone does not heal the trauma of losing patients. The shift reflects a growing recognition that physician burnout and compassion fatigue undermine the quality of care.
Among the notable presentations were advances in immunotherapy for Merkel cell carcinoma and real-world evidence on GLP-1 drugs' impact on cancer risk. Grail also presented updated performance data on its multi-cancer early detection test, showing improved specificity.
However, barriers to care remained a dominant theme. Experts highlighted disparities in access to novel therapies, particularly for underserved populations, and called for policy changes to ensure equitable distribution of breakthroughs.
The grief-focused programming drew mixed reactions. Some attendees appreciated the humanization of the conference, while critics worried it detracted from the scientific urgency of new treatment data.